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ORIGINAL ARTICLE

Consensus Treatment Plans for Chronic
Nonbacterial Osteomyelitis Refractory to
Nonsteroidal Antiinflammatory Drugs
and/or With Active Spinal Lesions
YONGDONG ZHAO ,1 EVELINE Y. WU,2 MELISSA S. OLIVER,3 ASHLEY M. COOPER,4
MATTHEW L. BASIAGA ,1 SHEETAL S. VORA,5 TZIELAN C. LEE,3 EMILY FOX,4 GIL AMARILYO,6
SARA M. STERN,7 JEFFREY A. DVERGSTEN,8 KATHLEEN A. HAINES,9 KELLY A. ROUSTER-STEVENS,10
KAREN B. ONEL,11 JULIE CHERIAN,12 JONATHAN S. HAUSMANN,13 PAIVI MIETTUNEN,14
TANIA CELLUCCI,15 FARZANA NURUZZAMAN,12 ANGELA TANEJA,10 KARYL S. BARRON,16
MATTHEW C. HOLLANDER,17 SIVIA K. LAPIDUS,18 SUZANNE C. LI ,9 SEZA OZEN,19
HERMANN GIRSCHICK,20 RONALD M. LAXER,21 FATMA DEDEOGLU,22 CHRISTIAN M. HEDRICH,23
POLLY J. FERGUSON,24 AND THE CHRONIC NONBACTERIAL OSTEOMYELITIS/CHRONIC RECURRENT
MULTIFOCAL OSTEOMYELITIS STUDY GROUP AND THE CHILDHOOD ARTHRITIS AND
RHEUMATOLOGY RESEARCH ALLIANCE SCLERODERMA, VASCULITIS, AUTOINFLAMMATORY
AND RARE DISEASES SUBCOMMITTEE
Objective. To develop standardized treatment regimens for chronic nonbacterial osteomyelitis (CNO), also known as
chronic recurrent multifocal osteomyelitis (CRMO), to enable comparative effectiveness treatment studies.
Methods. Virtual and face-to-face discussions and meetings were held within the CNO/CRMO subgroup of the Childhood
Arthritis and Rheumatology Research Alliance (CARRA). A literature search was conducted, and CARRA membership
was surveyed to evaluate available treatment data and identify current treatment practices. Nominal group technique was
used to achieve consensus on treatment plans for CNO refractory to nonsteroidal antiinflammatory drug (NSAID)
monotherapy and/or with active spinal lesions.
Results. Three consensus treatment plans (CTPs) were developed for the first 12 months of therapy for CNO patients refractory to NSAID monotherapy and/or with active spinal lesions. The 3 CTPs are methotrexate or sulfasalazine, tumor necrosis
factor inhibitors with optional methotrexate, and bisphosphonates. Short courses of glucocorticoids and continuation of
NSAIDs are permitted for all regimens. Consensus was achieved on these CTPs among CARRA members. Consensus was
also reached on subject eligibility criteria, initial evaluations that should be conducted prior to the initiation of CTPs, and
data items to collect to assess treatment response.
Conclusion. Three consensus treatment plans were developed for pediatric patients with CNO refractory to NSAIDs and/
or with active spinal lesions. Use of these CTPs will provide additional information on efficacy and will generate meaningful data for comparative effectiveness research in CNO.

Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease that mainly affects children and adolescents. Clinical presentations range from mild and sometimes
limited unifocal disease to severe, chronically active or recurrent inflammation of multiple bones. The latter is referred to

as chronic recurrent multifocal osteomyelitis (CRMO). Here,
we will use the term CNO to refer to the entire spectrum of
this disease. CNO can be complicated by vertebral compression fractures, kyphosis, and leg length discrepancy when it
is not recognized early or treated adequately. The diagnosis
of CNO is made by excluding alternatives in the differential diagnosis, including malignancy (leukemia, lym-

The Childhood Arthritis and Rheumatology Research Alliance was supported by the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, Friends of CARRA, and the
Arthritis Foundation. Dr. Zhao was supported by the Clinical
Research Scholar Program from the Seattle Children’s Research
Institute and the Childhood Arthritis and Rheumatology

Research Alliance. Drs. Basiaga’s and Ferguson’s work was
supported by the NIH (grants T32-GM-075766-09 and NIAMS
R01-AR-059703, respectively). Dr. Hedrich’s work was supported by the Fritz Thuyssen Foundation, the Novartis Foundation for Therapeutic Research, and the intramural MeDDrive
Program at the University of Technology Dresden.

INTRODUCTION

1228

CTP for Refractory CNO and CRMO

Significance & Innovations
•

Three standardized consensus treatment plans
were developed for patients with chronic nonbacterial osteomyelitis (CNO) who have had insufficient response to nonsteroidal antiinflammatory
drugs and/or who have active spinal lesions.
The consensus treatment plans developed by
members of the Childhood Arthritis and Rheumatology Research Alliance are the first ever for
patients with CNO.
Use of these treatment plans will allow for evaluation of these medications in patients with CNO in
future comparative effectiveness research studies.

•
•
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The developed CTPs were based on the best available evidence and current treatment practices, and generated through
consensus methodology including nominal group techniques. The intention of these CTPs was to limit treatment
practice variation in order to enable researchers to conduct
comparative effectiveness studies. Because of the variability
in the second-line treatment of CNO, we have worked to
develop standardized treatment plans and data collection
forms and measures for CNO patients with a nonsteroidal
antiinflammatory drug (NSAID)-refractory course and/or with
active spinal lesions. These CTPs will facilitate future comparative effectiveness studies for CNO. It must be noted that
CTPs are not meant to be clinical care guidelines. A treating
physician may deviate from the CTP at any time if it is
deemed appropriate for the patient’s care.

MATERIALS AND METHODS
phoma, and primary or metastatic bone tumors), Langerhans’ cell histiocytosis, and infection. Clinical assessment in
conjunction with serum inflammatory parameters and imaging studies, particularly magnetic resonance imaging (MRI),
are crucial for the diagnosis and monitoring of disease activity
of CNO (1).
Because of significant variation in clinical treatment practices among pediatric rheumatologists, standardized treatment regimens (consensus treatment plans [CTPs]) have been
developed within the Childhood Arthritis and Rheumatology
Research Alliance (CARRA), a North American organization
composed of pediatric rheumatologists and researchers, for
systemic juvenile idiopathic arthritis (JIA) (2), polyarticular
JIA (3), lupus nephritis (4), juvenile localized scleroderma
(5), and juvenile dermatomyositis (6). These CTPs enable
progress to be made toward identifying optimal treatment for
these diseases through prospective observational studies.

1

Yongdong Zhao, MD, PhD, Matthew L. Basiaga, DO, MSCE:
Seattle Children’s Hospital, University of Washington, Seattle;
2
Eveline Y. Wu, MD, MSCR: University of North Carolina,
Chapel Hill; 3Melissa S. Oliver, MD, MS, Tzielan C. Lee, MD:
Stanford Children’s Health, Stanford University, Palo Alto,
California; 4Ashley M. Cooper, MD, Emily Fox, MD, MS: Children’s Mercy, Kansas City, Missouri; 5Sheetal S. Vora, MD,
MS: Levine Children’s Hospital, Charlotte, North Carolina; 6Gil
Amarilyo, MD: Schneider Children’s Medical Center of Israel,
Petach Tikva Israel, and Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israel; 7Sara M. Stern, MD: University of
Utah, Salt Lake City; 8Jeffrey A. Dvergsten, MD: Duke Children’s Hospital, Durham, North Carolina; 9Kathleen A. Haines,
MD, Suzanne C. Li, MD, PhD: Joseph M. Sanzari Children’s
Hospital, Hackensack University Medical Center, Hackensack,
New Jersey; 10Kelly A. Rouster-Stevens, MD, PharmD, Angela
Taneja, MD: Children’s Healthcare of Atlanta, Emory University, Atlanta, Georgia; 11Karen B. Onel, MD: Hospital for Special Surgery, New York, New York; 12Julie Cherian, MD,
Farzana Nuruzzaman, MD: Stony Brook Children’s Hospital,
Stony Brook, New York; 13Jonathan S. Hausmann, MD: Boston
Children’s Hospital and Beth Israel Deaconess Medical Center,
Boston, Massachusetts; 14Paivi Miettunen, MD: University of
Calgary, Calgary, Alberta, Canada; 15Tania Cellucci, MD,
MScCH: McMaster Children’s Hospital, Hamilton, Ontario,
Canada; 16Karyl S. Barron, MD: National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda,

The CARRA CNO workgroup of the CARRA Scleroderma,
Vasculitis, Autoinflammatory and Rare Diseases (SVARD)
subcommittee consists of board-certified pediatric rheumatologists with special interest and expertise in CNO, as well
as family representatives. The CARRA CNO workgroup
reviewed evidence published between 1966 and April 29,
2015. A literature search was conducted using PubMed
with the following medical subject headings (MeSH) terms:
SAPHO[all fields] OR (chronic[all fields] AND nonbacterial
[all fields] AND (“osteomyelitis”[MeSH terms] OR “osteomyelitis”[all fields])) OR (“chronic recurrent multifocal
osteomyelitis”[supplementary concept] OR “chronic recurrent multifocal “osteomyelitis”[all fields] OR “chronic
recurrent multifocal osteomyelitis”[all fields]) OR (noninfectious[all fields] AND (“osteomyelitis”[MeSH terms] OR
“osteomyelitis”[all fields])) AND (hasabstract[text] AND
“humans”[MeSH terms] AND English[lang]).

Maryland; 17Matthew C. Hollander, MD, MHA: University of
Vermont Medical Center, Burlington; 18Sivia K. Lapidus, MD:
Goryeb Children’s Hospital, Morristown, New Jersey; 19Seza
Ozen, MD: Hacettepe University, Ankara, Turkey; 20Hermann
Girschick, MD: Vivantes Children’s Hospital in Friedrichshain,
Berlin, Germany; 21Ronald M. Laxer, MDCM, FRCPC: The
Hospital for Sick Children and University of Toronto, Toronto,
Ontario, Canada; 22Fatma Dedeoglu, MD: Boston Children’s
Hospital, Harvard Medical School, Boston, Massachusetts;
23
Christian M. Hedrich, MD, PhD: Children’s Hospital Dresden,
University Medical Center Carl Gustav Carus, TU Dresden,
Dresden, Germany, and Institute of Translational Medicine,
University of Liverpool, and Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool, UK; 24Polly J. Ferguson, MD:
University of Iowa Carver College of Medicine, Iowa City.
Dr. Amarilyo has received consulting fees from Novartis
(less than $10,000). Dr. Ozen has received consulting and/or
speaking fees from Novartis, Roche, and R-Pharm (less than
$10,000 each). Dr. Laxer has received consulting fees from
AbbVie and Novartis and Advisory Board fees from AbbVie
and Sobi (less than $10,000 each). Dr. Dedeoglu has received
Advisory Board fees from Novartis (less than $10,000).
Address correspondence to Yongdong Zhao, MD, PhD,
MA 7.110, 4800 Sand Point Way NE, Seattle, WA 98105.
E-mail: yongdong.zhao@seattlechildrens.org.
Submitted for publication June 29, 2017; accepted in
revised form October 31, 2017.
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In total, 398 articles were screened. A complete list of the
results is included in Supplementary Appendix A, available on
the Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23462/abstract. There were no randomized controlled trials or case–control studies in CNO.
Therefore, case series, historical cohort studies, and prospective
observational studies with at least 3 months of followup data in
the pediatric population were included for review. Twenty-one
articles met the criteria. Eleven additional articles published
between April 29, 2015, and January 1, 2017, were later
included. The group formulated clinical scenarios, analyzed
survey responses from CNO workgroup members, organized
consensus meetings, and finalized treatment plans. Levels of
evidence were graded from 2 to 5 according to guidelines established by the Oxford Centre for Evidence-Based Medicine
(www.cebm.net).
Planning meetings. Members of the CARRA CNO
workgroup initiated the process to develop CTPs at the
CARRA 2014 annual meeting. Monthly conference calls
within the workgroup were then used to develop a CARRA
members’ survey and ongoing discussion of the CTPs. The
targeted population included patients refractory to NSAID
monotherapy and/or with active spinal lesions, because
physicians perceived less favorable outcomes and need for
additional treatment in such patients. At the planning
meeting (April 2015 in Austin, Texas), a survey was sent to
the SVARD subcommittee to collect responses of diagnostic,
disease monitoring, and therapeutic approaches chosen
by CARRA-affiliated pediatric rheumatologists. Further
discussion at that meeting outlined the core substance of the
planned CTPs. A detailed survey was sent to the CNO group
(67% of 34 members responded) asking for comments on
summarized plans and proposed options (see Supplementary
Appendix B, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23462/
abstract). At the American College of Rheumatology Annual
Meeting (November 2015 in San Francisco, California), a
second meeting was attended by 13 pediatric rheumatologists. Patient characteristics, treatment options, and
imaging monitoring were discussed in depth.
Consensus meetings. At the CARRA annual meeting
(April 2016 in Toronto, Ontario, Canada), a CNO meeting
was attended by 6 family representatives and 30 pediatric
rheumatologists, one of whom acted as the facilitator (YZ).
The facilitator and family representatives participated in the
discussion but were not eligible to vote. Nominal group
technique was used to achieve consensus (defined as ≥80%
agreement within the group) on all questions considered
during the meeting and subsequent conference calls. The
facilitator framed the question to be discussed and presented
data from the survey relevant to each question. Potential
responses to the question were shown based on prior group
discussion. Each participant had the opportunity to express
his or her opinion for 1–2 minutes without interruption.
Potential responses were updated accordingly.
Participants were then given the opportunity to vote for
their preferred responses to the questions using a show-ofhands vote. A vote of ≥80% positive or negative was considered a consensus vote. If consensus was not achieved,
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participants were given the opportunity to speak uninterrupted for 1–2 minutes to share their thought process. After
excluding answers that would not result in consensus votes,
or after modifying potential responses, another vote was
taken. If necessary, this process continued for 2 rounds on
each question. If a clear consensus was not reached after 2
rounds, the decision was made to move to the next question.

RESULTS
What standardized disease-assessment tools of CNO have
been reported? A literature review of the clinical cohort
studies on CRMO, CNO, and pediatric synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome revealed a lack of agreement on a standardized evaluation tool.
Two articles have reported standardized assessments with
level IV evidence. Beck and colleagues used a PedCNO score
(7) to assess prospectively the responses to naproxen in 37
children with CNO. After 12 months of treatment, 54% of
patients achieved PedCNO 70 (at least 70% improvement in
at least 3 of 5 core variables and no more than 1 of the
remaining variables deteriorating by more than 70%). Within
the core set, the erythrocyte sedimentation rate (ESR) and the
Childhood Health Assessment Questionnaire (C-HAQ) had a
floor effect by 3 months, whereas the number of radiologic
lesions by MRI, severity of disease estimated by the physician, and severity of disease estimated by the patient or
parent continued to improve over 12 months. Zhao and colleagues further described the characteristics of CNO lesions
based on MRI findings using a grading system to score the
severity of bone edema and soft tissue inflammation as well
as the presence of periosteal reaction, hyperostosis, growth
plate damage and vertebral compression (8). Applying this
scoring tool to 2 retrospective cohorts of patients with CNO,
the authors found a significant decrease in the number of
nonvertebral lesions and the maximum severity of bone
edema in the group receiving aggressive treatment.
What evidence of the effectiveness of second-line treatments is there in CNO? Studies focusing on children with
CNO who failed to respond to NSAID treatment are limited.
Seven articles have reported on pamidronate treatment in CNO with level IV evidence. Kerrison and colleagues
reported significant pain relief and improved activity and
well-being with pamidronate use in 7 children (3 with spinal
lesions) who failed to respond to NSAIDs (9). Simm et al (10)
and Miettunen et al (11) demonstrated the effectiveness of
pamidronate in children with CNO refractory to NSAIDs.
More than 80% of patients had pain relief and more than
90% of patients in Miettunen’s study exhibited resolution of
bone lesions on MRI after 6 months of treatment. Gleeson
and colleagues reported pain relief with pamidronate in 6 of
7 children who failed to respond to NSAIDs (12). Among 5
children with spinal fractures, 3 had followup radiographs
showing regression of height loss in affected vertebrae in
response to pamidronate therapy. Hospach et al (13) reported
complete resolution of hyperintensity signal of active spinal
lesions after 3 to 6 cycles of pamidronate and a median
interval of 13 months of followup with MRI in 8 of 9 children
with CNO refractory to NSAIDs. Roderick et al treated 11
children with CNO refractory to NSAIDs with 4 cycles of
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pamidronate at 1 mg/kg/day on 3 consecutive days every 3
months (14). Two patients exhibited a good response, 6
showed a moderate response, 1 had a mild response, and 2
failed to respond based on repeated whole-body MRIs.
Schnabel et al described pamidronate to be highly effective
in CNO patients refractory to standard treatment with
NSAIDs and/or glucocorticoids (15).
Published data on the use of tumor necrosis factor (TNF)
inhibitors in CNO are more limited. Eight articles have
reported treatment with TNF inhibitors in CNO with level
IV evidence. A small cohort study (n = 4) by Eleftheriou et al
showed decreased pain in children with CNO after infliximab treatment (n = 3) and anakinra (n = 1, later switched to
adalimumab) (16). Borzutzky et al (17) and Wipff et al (18)
observed the highest rates of clinical remission (46%) or efficacy (89%) from TNF inhibitors compared to glucocorticoids, methotrexate (MTX), sulfasalazine (SSZ), and
NSAIDs. Jansson et al (19) reported disease remission
induced by infliximab in 2 patients who failed to respond to
NSAIDs, glucocorticoids, disease-modifying antirheumatic
drugs (DMARDs), and pamidronate. Recently, a combination of infliximab and methotrexate with or without zolendronic acid significantly improved clinical, laboratory, and
imaging results in 9 children with CNO (8). However, Kaiser
et al found poor response to TNF inhibitors in children with
CNO, i.e., only 2 of 7 patients achieved remission (not
defined) (20). Conversely, in a small childhood series, etanercept was effective in all 5 patients (21). Anti–interleukin-1
(IL-1) has been reported in fewer pediatric cases (20). In an
adult cohort (n = 6), anakinra improved the patient global
assessment of disease activity within 1 month in 5 patients
(22).
Most of the studies in the literature reported variable success of MTX and SSZ in patients with poor responses to
NSAIDs or frequent relapses. Other DMARDs were rarely
used. Five articles have reported treatment of DMARDs in
CNO with level IV evidence. Jansson et al (19), Catalano-Pons
et al (23), and Kaiser et al (20) documented poor responses to
SSZ, MTX, and azathioprine in children with CNO. Borzutzky et al (17) and Wipff et al (18) showed relatively lower
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rates of remission (18–20%) and efficacy (38–41%) in children treated with MTX or SSZ. There was poor tolerance of
MTX, and dosing was not reported in most studies.
Currently, there is no consensus on subsequent treatment
for patients refractory to NSAID treatment. Based on a survey sent to members of CARRA, 95% of treating physicians
(41% response rate) reported the use of NSAIDs as the firstline treatment in children with a new diagnosis of CNO (evidence level V) (24). For patients who failed to respond to
NSAID treatment, the most commonly used treatments were
reported to be MTX (67%), TNF inhibitors (65%), and bisphosphonates (46%) (24). These results guided the development of CTPs.
What patient characteristics should be included for this
CTP? The initial intent was to include all children with
CNO. However, through further workgroup discussion, it
was agreed that NSAIDs were generally considered first-line
treatment for all newly diagnosed patients without active
spinal lesions. Therefore, our attention turned to a more
defined subset: patients refractory to NSAIDs and/or with
active spinal lesions. The definition of “refractory to
NSAIDs” was debated among group members, and the
duration of the initial NSAID trial was set at a minimum of 4
weeks. Based on the physician’s discretion and the disease
severity, further treatment may be initiated. The rationale of
including active spinal lesions as a patient characteristic is
the perceived significance of increased risk of vertebral
fracture (11–13). The age limit for the CTP was set to 21
years, because children and adults younger than 21 years of
age are commonly seen and followed in children’s hospitals.
Patients with malignancy, infectious osteomyelitis, or other
contraindications to the proposed treatment agents were not
eligible for the CTP. Characteristics of the patients are
shown in detail in Table 1.
What standardized data should be collected at the initial
evaluation? Each patient should undergo a complete clinical
assessment, including comprehensive musculoskeletal exam,
since clinically active lesions are defined by findings of focal

Table 1. Patient characteristics for pediatric chronic nonbacterial osteomyelitis refractory to NSAID monotherapy and/
or with active spinal lesions*
Enrolled patients should have:
Age at enrollment 21 years or younger
Presence of bone edema on STIR or T2 fat saturation sequence on MRI within 12 weeks of enrollment
Whole-body imaging evaluation (either whole-body MRI or bone scintigraphy)†
Active disease after failing at least 4 weeks of NSAIDs and/or presence of active spinal lesions, regardless of NSAID trial‡
Bone biopsy to exclude infection or malignancy unless bone lesions follow typical distribution or there is IBD, psoriasis, or
palmar plantar pustulosis§
Enrolled patients should NOT have:
History of or current malignancy
Current infectious osteomyelitis
Contraindication to the selected treatment agent
* NSAID = nonsteroidal antiinflammatory drug; STIR = short tau inversion recovery sequence; MRI = magnetic resonance imaging; IBD = inflammatory bowel disease.
† Suggested protocol includes STIR or fat saturation sequences of coronal views of whole body and sagittal view of total spine. Some patients may
require dedicated views of hands or feet when lesions in these areas are present. Gadolinium is not required.
‡ Active disease defined as persistent pain with focal tenderness and/or warmth and/or persistence of bone edema on MRI in at least 1 lesion site.
Active spinal lesions are defined as bone edema within at least 1 vertebral body of the cervical, thoracic, or lumbar spine.
§ Typical distribution of lesions includes the clavicle or symmetrical lesions in long bones at metaphysis/epiphysis.
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tenderness, and/or swelling, and/or warmth, in addition to
the patient’s report of pain. Active joint counts with arthritis
and enthesitis are important to record because of reported
overlap between enthesitis-related arthritis (ERA) and CNO.
Due to the lack of validated CNO-specific patient-reported
outcomes, both the C-HAQ and Patient-Reported Outcomes
Measurement Information System (PROMIS) should be
administered. Based on the previously published CNO
diagnostic criteria (19,25) and results from physician surveys
(24), a bone biopsy is recommended, unless typical lesions
including the clavicle or symmetrical lesions at metaphysis/
epiphysis of long bones, or comorbidities such as inflammatory bowel disease, palmoplantar pustulosis, or psoriasis,
are present. All participants agreed that whole-body imaging
is required to identify all bone lesions. Whole-body MRI is
preferred (26). A suggested protocol is included in Table 1.
Bone scintigraphy is considered an adequate alternative if
whole-body MRI is not available. The total number of bone
lesions is recorded as per the radiologist’s report. A baseline
MRI (whole body or regional) is required to define active bone
lesions based on the presence of bone marrow edema from
short tau inversion recovery (STIR) or T2 fat saturation
sequences, as the MRI findings are important to guide treatment decisions and to monitor disease activity (8,11,13,24,27).
The normal range of bone marrow signal on MRI has not been
established yet. Therefore, distinguishing abnormal marrow

signal is subject to the experience of the radiologist reading
the image. The size and severity of bone edema and/or soft
tissue inflammation is determined by the radiologist based on
previous description (8). Bony expansion, growth plate
damage, and vertebral compression were considered disease
damage and not active inflammation (8). In children treated
with bisphosphonates, a linear hyperintense signal should
not be mistaken for active lesions. Laboratory data, including
complete blood cell counts, ESR, and C-reactive protein (CRP)
level, are required for disease monitoring. Alkaline phosphatase at baseline is required to screen for metabolic bone
disease. HLA–B27 has been reported to be associated with
cutaneous diseases in CNO and to have a strong association with
ERA. Thus, participants agreed to include HLA–B27 testing.
What are the most important therapies to include? We
reviewed the literature for medications with reported
efficacy in CNO refractory to NSAIDs, including nonbiologic DMARDs, TNF inhibitors, and bisphosphonates
(8–14,17,18,20,28,29). There are no head-to-head comparisons among these treatments, even though current data
suggested higher remission rates in children treated with
TNFi than those treated with DMARDs (17,18). Among
CARRA physicians, MTX, TNF inhibitors, and bisphosphonates were the most commonly used medications in
children with CNO who failed to respond to NSAIDs (24).

Table 2. Consensus treatment plans for the first 6–12 months*
Treatment plan A: nonbiologic DMARDs
Methotrexate (oral or subcutaneous): 15 mg/m2 (maximum 25 mg/dose) weekly
OR
Sulfasalazine (oral): 50 mg/kg/day (maximum 1,500 mg/dose) divided twice daily
Treatment plan B: TNF inhibitors with or without methotrexate
Adalimumab (subcutaneous): 20 mg every other week for body weight 15–30 kg; 40 mg every other week
for body weight ≥30 kg. May increase to weekly.
OR
Etanercept (subcutaneous): 0.8 mg/kg (maximum 50 mg/dose) weekly. May split into twice a week.
OR
Infliximab (intravenous): 5–10 mg/kg (maximum 1,000 mg/dose) at week 0, 2, and 6, then every
4–8 weeks
OR
Other TNF inhibitor at discretion of treating physician
Optional: concomitant methotrexate (do not need to follow treatment protocol; may use lower dosing,
i.e., 5–10 mg/m2)
Treatment plan C: bisphosphonates
Pamidronate (intravenous)
Option 1: 1 mg/kg/dose (maximum 60 mg/dose) every month†
Option 2: 1 mg/kg/dose for 3 consecutive days every 3 months†
OR
Zolendronic acid (intravenous): initial dose 0.0125–0.025 mg/kg every 6 months. May increase dose to
0.05 mg/kg/dose (maximum 4 mg/dose)
All options allow concurrent use of
NSAIDs‡
Glucocorticoids: up to a total of 6 weeks of treatment with or without tapering, with an upper limit of
2 mg/kg/day (equivalent dosing of prednisone, maximum 60 mg daily)
* With the exception of bisphosphonates (minimum 3–6 months), the minimum treatment duration should be 12 months.
DMARD = disease-modifying antirheumatic drug; TNF = tumor necrosis factor; NSAID = nonsteroidal anti-inflammatory
drug.
† A lower dose of 0.5 mg/kg may be used at initiation of treatment. Both options should continue for a minimum duration
of 3 months. Maximum cumulative dose is 11.5 mg/kg/year.
‡ For details on dosing, see Supplementary Appendix C, available on the Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23462/abstract.
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Consensus was reached to include the 3 most commonly
applied combinations of medications in the final CTPs.
There was a discussion about whether concomitant
NSAIDs and/or oral glucocorticoid “bursts” were allowed.
The group decided on the optional use of both, with limits
on the allowable duration of glucocorticoids due to their
known side effects. Glucocorticoid “bursts” were defined
as glucocorticoids (equivalent dosing of prednisone) up to
2 mg/kg/day (maximum daily dose of 60 mg) for up to a
total of 6 weeks of treatment with or without tapering.
Chosen strategies were in agreement with current practice
echoed by participants. In patients treated with TNF
inhibitors, concomitant MTX was allowed to suppress the
formation of human antichimeric anti-TNF antibody
production (particularly with infliximab) as well as for
combination therapy (Table 2).
What dose/route/frequency should be used for each medication in the CTPs? The most commonly used DMARD by
physician members in the CARRA survey was MTX (34%)
(24). However, within the CNO group, members reported that
SSZ was commonly used based on personal experience.
Thus, only these 2 DMARDs were included in the protocol.
TNF inhibitors reported for use in CNO were limited to
etanercept, adalimumab, and infliximab. The frequency of
using these TNF inhibitors among surveyed CARRA physician members was 26% with adalimumab and infliximab,
and 17% with etanercept (24). Thus, all 3 were included in
the protocol. Other TNF inhibitors may be used by the
treating physician with discretion. Mandatory tuberculosis
screening is required prior to the initiation of a TNF inhibitor. The dosing of DMARDs and TNF inhibitors followed
standard JIA treatment regimens as reported in the literature
and clinical practice (Table 2). Pamidronate was the most
commonly reported bisphosphonate (9–15), whereas zolendronic acid was only reported as concomitant treatment in a
single study (8). However, both were used by physicians
within CARRA (pamidronate 79%, zolendronic acid 21%)
(24). Therefore, in the bisphosphonate arm, pamidronate and
zolendronic acid were both included in the protocol. The
dosing of bisphosphonates was based on the pediatric
endocrinology literature and has been utilized in case series
of CNO and SAPHO patients (Table 2). Suggested toxicity
monitoring and immunizations are included in Supplementary Appendix C, available on the Arthritis Care &
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Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.23462/abstract.
What criteria should be used to determine treatment
failure? Various parameters have been used to define
treatment response in CNO, including the PedCNO score (7),
total number of clinically active bone lesions, and severity of
bone edema and soft tissue inflammation on MRI (8). After
discussion, group consensus was reached to use a composite
score similar to the JIA core set based on significant variation
of symptoms and a high incidence of pain amplification
(pain in the absence of inflammatory activity) among CNO
patients. Various items were proposed by group members,
and after in-depth discussion, the group identified the top 6
individual items. These treatment response criteria are considered expert opinion (evidence level IV). Thus a modified
composite score was proposed by replacing the C-HAQ and
severity of disease estimated by patient or parent with the
size and severity of bone marrow edema and/or soft tissue
inflammation in the MRI and the total count of clinically
active lesions. These criteria have not been validated and are
merely suggestions for physicians to consider during their
clinical management of children with CNO. As shown in
Table 3, a combination of criteria for treatment failure
include the following: patient pain, as measured by visual
analog scale (VAS), total number of clinically active lesions
(defined as focal tenderness, and/or swelling, and/or warmth
in addition to patient’s report of pain at a known CNO lesion
site), physician evaluation of disease activity as measured on
a 10-cm Likert scale (VAS), number of radiologic lesions by
whole-body MRI or bone scintigraphy, maximum severity of
marrow edema of CNO lesions on imaging, and abnormal
ESR and/or CRP level after exclusion of other potential
causes. The C-HAQ was not included because of its floor
effect and lack of applicability to the majority of CNO patients according to CNO group members’ experience. Treatment failure at 3 months was defined as no improvement in
at least 4 of the 6 criteria, or no improvement in ≥50% of applicable criteria if not all were available. Treatment success
(complete resolution) was defined as resolution of pain,
normalization of ESR and CRP level, and resolution of bone
marrow edema in MRI, as reported previously (17–19).
Management of CNO patients at followup visits will
depend on the overall assessment of disease activity by the
physician, because there are no validated criteria at this time.

Table 3. Criteria for treatment failure at 3 months (when a patient fails to improve
on at least 4 of 6 of the criteria or on >50% of applicable criteria)*
1)
2)
3)
4)
5)
6)

Patient pain as measured by VAS
Total number of clinically active lesions†
Number of radiologic lesions by whole-body MRI or bone scintigraphy
Size and degree of bone marrow edema of CNO lesions and/or presence of soft tissue
swelling/inflammation related to CNO lesion on imaging
Physician VAS
Abnormal ESR and/or CRP level after exclusion of other potential causes‡

* VAS = visual analog scale; CNO = chronic nonbacterial osteomyelitis; MRI: magnetic resonance
imaging; ESR = erythrocyte sedimentation rate; CRP = C- reactive protein.
† Defined as a body part with focal tenderness, and/or swelling, and/or warmth in addition to
patient’s report of pain at a known CNO lesion site.
‡ Abnormal ESR defined as ≥20 mm/hour and abnormal CRP as ≥1 mg/dl.
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TREATMENT PLANS

A

B

C

At 3 months
(and follow up visits)

IMPROVED

UNCHANGED or WORSENED

By physician assessment

Continue current treatment

●
●

By physician assessment

Consider switching to or adding another
treatment
(may switch to another agent
within same plan)

ASSESS in 3 months
If improved, follow IMPROVED
If unchanged or worsened, follow
UNCHANGED or WORSENED
●
●

ASSESS in 1 - 3 months
If improved, follow IMPROVED
If unchanged or worsened, consider
another treatment or reconsider
diagnosis if necessary

Figure 1. Summary of protocols. CNO = chronic nonbacterial osteomyelitis; NSAID = nonsteroidal antiinflammatory drug.

At the 3-month followup visit, an escalation of treatment,
such as switching medications within an arm or switching to
a different arm is recommended if there is worsening of the
disease or no improvement based on the treating physician’s
assessment (Figure 1). Otherwise, maintaining current treatment is recommended. With the exception of bisphosphonates (3–6 months), minimum treatment duration should be
12 months based on the chronic nature of CNO, poor
response to previous NSAID treatment, and the risk of vertebral compression fractures.
At what intervals should patients be followed for the
purposes of data collection? Consensus was reached to
follow intended CNO patients a minimum of every 3 months
for the first year. The followup visit may occur earlier if the
physician has concerns about the clinical course and/or
treatment response. In addition to routine history, physical
examinations, and laboratory testing, MRI is strongly
recommended to objectively assess disease activity at 6
and 12 months after adjusting therapy. Additional imaging
is recommended in suspected disease flares or persistent
activity despite treatment escalation. Whole-body MRI is
generally preferred, but regional MRI of known sites is
acceptable in unifocal disease or if whole-body MRI is not
available.
Data collection at followup and final approval of the CTP
by CARRA members. Consensus was reached to minimize
data collection for practicability using a standardized form.
The clinical parameters, imaging tests, and laboratory tests
considered essential for CNO followup assessment are
shown in Table 4. A final survey was sent to 337 active
voting members of CARRA in April 2017 (see Supplementary Appendix D, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.23462/abstract). A total of 275 responses were received, for a response rate of 82%. Of the respondents, 254
were attending pediatric rheumatologists in North America
who have cared for children with CNO. Of these 254
respondents, a total of 216 (85%) completed the entire
survey. Most respondents (70%) had 1–4 patients with
CNO who either failed to respond to NSAID treatment or

had active spinal lesions over the last 12 months, whereas
14% had none and 16% had 5 or more.
The survey results showed that more than 90% of
respondents agreed with the patient characteristics, treatment plans, and definition of treatment failure. Within
the treatment plans, 78%, 90%, and 50% of 228 responders use DMARDs, TNF inhibitors, or bisphosphonates,
respectively, on children who fail to respond to NSAIDs;
62%, 94%, and 73% of 221 responders are willing to use
these respective treatment plans on children with active
spinal lesions.

DISCUSSION
To our knowledge, these are the first CTPs developed for
children with CNO by members of a professional society.
Our work demonstrates the feasibility of achieving consensus in treatment plans and data collection for a rare and
understudied pediatric rheumatic disease using a combination of surveys, a comprehensive literature search, and
nominal group technique.
Lack of validated criteria for classification and followup, as
well as standardized treatment, has hindered the progress
of comparative effectiveness research in CNO. Current
approaches are solely based on small case series, personal
experience, and expert opinion (1). Our work is one step forward toward standardizing applied treatment regimens based
on existing data and collection of a minimal set of data. This
may allow objective evaluation of the effectiveness of different treatments. In addition, consistent imaging data collection will provide important corroboration with patientreported outcomes and the physician’s clinical assessment.
The CTPs presented here reflect the current clinical practice of CARRA members. Thus, they are highly applicable
and more likely to be adopted in daily practice by practitioners. The intent behind these CTPs is to reduce the variation of applied treatment options so that meaningful data
from as many patients as possible can be collected in an
observational study.
Of note, the proposed treatment plans are standardized
regimens without strong evidence of which treatment is
optimal. They are not to be misinterpreted as guidelines, as
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Table 4. Suggested minimum data collection and assessment intervals to be used
with treatment plans*
Proposed variables

Baseline

History
Demographics
Date of birth
Sex
Race and ethnicity
Clinical symptoms
Fever
Rash
Gastroenterological symptoms
Bone pain
Limitation of motor functions†
Pre-enrollment treatment history for CNO
Family history of CNO-associated conditions‡
Past medical history/concurrently CNO-associated conditions‡
Current medications and doses
Patient-reported outcomes and global assessments
Pain
Health-related quality of life
Physical function (C-HAQ, PROMIS)
Parent/patient global assessment of disease activity
Physician global assessment of disease activity
Physical examination
Height and weight
Clinically active CNO lesion count
Active joint counts
Enthesitis
Rash
Imaging findings
MRI (whole body preferred if available)
Bone scintigraphy if whole-body MRI not available
Radiograph if done
CT if done
DXA if done
Laboratory findings
CBC with differential
C-reactive protein level
Erythrocyte sedimentation rate
Alkaline phosphatase
HLA–B27
Bone biopsy findings§
Bacterial, fungal, and AFB culture
Pathology
Treatment plan–related items
Serious adverse events or important medical event
If plan discontinued, rationale
Number of glucocorticoid burst, if any

Followup

x
x
x
x
x
x
x
x
x
x
x
x

x
x

x
x
x
x
x

x
x
x
x
x

x
x
x
x
x

x
x
x
x
x

x
x
x
x
x

x

x
x
x
x
x

x
x
x
x
x

x
x
x
x
x
x

x
x
x
x
x

* Data are collected at baseline and at followup visits every 2–3 months. CNO = chronic nonbacterial
osteomyelitis; C-HAQ = Childhood Health Assessment Questionnaire; PROMIS = Patient-Reported Outcomes Measurement Information System; MRI: magnetic resonance imaging; CT = computed tomography; DXA = dual-energy X ray absorptiometry; CBC = complete blood cell count.
† Prolonged school/daycare absences, limited use of upper body, difficulty bearing weight, requiring
crutches, bedridden from spinal/leg pain.
‡ Psoriasis, inflammatory bowel disease, celiac disease, inflammatory arthritis, or spondyloarthropathy.
§ Needed when bone lesions do not follow typical distribution (clavicle or symmetrical lesions in long
bones at metaphysis/epiphysis) in the absence of CNO-associated conditions.

their intention is to enable further study to identify optimal
treatment. These CTPs currently do not include any biologic treatments other than TNF inhibitors, because of the
rarity of their use in CNO and a lack of support by the available literature. However, these CTPs may be revised in the

future to include other potentially effective forms of treatment as more evidence becomes available.
Bone biopsy was not required for all children with CNO
(18,25). However, other diagnoses must be excluded prior to
using these plans based on the treating physician’s thorough
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evaluation. These plans should only be used when physicians are confident of the diagnosis. Since whole-body MRI
offers the most thorough imaging evaluation for CNO without
exposure to radiation, it should be considered the gold standard. However, regional MRIs (or a series of multiple regional
MRIs) are considered reasonable when whole-body MRI is
not available. Other whole-body imaging, such as bone
scintigraphy, is considered an alternative one-time baseline
assessment whenever whole-body MRI is not available.
The CTP presented here has limitations. First, this CTP
does not extend beyond 12 months of treatment. Second,
this CTP does not include biologic treatments other than
TNF inhibitors. Third, validated disease monitoring scoring
tools are lacking, and the proposed criteria of treatment failure need further evaluation and validation.
In conclusion, 3 standardized CTPs were developed for
patients with CNO with insufficient response to NSAIDs
and/or the presence of active spinal lesions. Use of these
treatment plans will provide an opportunity to generate
meaningful data for future prospective observational studies to evaluate their effectiveness in children with CNO.
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